The estimated Net Worth of Christal M M Mickle is at least $52.6 millier dollars as of 22 March 2017. Ms Mickle owns over 2,000 units of Zevra Therapeutics Inc stock worth over $52,581 and over the last 10 years she sold KMPH stock worth over $0.
Sign up
Ms Mickle KMPH stock SEC Form 4 insiders trading
Ms has made over 3 trades of the Zevra Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she bought 2,000 units of KMPH stock worth $8,200 on 22 March 2017.
The largest trade she's ever made was buying 5,000 units of Zevra Therapeutics Inc stock on 17 August 2016 worth over $24,750. On average, Ms trades about 945 units every 36 days since 2015. As of 22 March 2017 she still owns at least 9,050 units of Zevra Therapeutics Inc stock.
You can see the complete history of Ms Mickle stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Christal M. M. Mickle biography
Christal M. M. Mickle is the Co-Founder and VP of Operations & Product Devel. at Zevra Therapeutics Inc.
How old is Ms Mickle?
Ms Mickle is 42, she's been the Co-Founder and VP of Operations & Product Devel. of Zevra Therapeutics Inc since . There are 11 older and 3 younger executives at Zevra Therapeutics Inc. The oldest executive at Zevra Therapeutics Inc is Richard W. Pascoe, 57, who is the Exec. Chairman.
What's Ms Mickle's mailing address?
Christal's mailing address filed with the SEC is C/O KEMPHARM, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, FL, 34747.
Insiders trading at Zevra Therapeutics Inc
Over the last 10 years, insiders at Zevra Therapeutics Inc have traded over $0 worth of Zevra Therapeutics Inc stock and bought 3,083,371 units worth $9,282,809 . The most active insiders traders include Street Capital Master Fund,..., David S Tierney et Travis C Mickle. On average, Zevra Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $246,727. The most recent stock trade was executed by R. La Duane Clifton on 13 January 2023, trading 635 units of KMPH stock currently worth $3,689.
What does Zevra Therapeutics Inc do?
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
What does Zevra Therapeutics Inc's logo look like?
Complete history of Ms Mickle stock trades at Zevra Therapeutics Inc
Zevra Therapeutics Inc executives and stock owners
Zevra Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Travis Mickle,
Chairman of the Board, President, Chief Executive Officer -
Dr. Travis C. Mickle Ph.D.,
Co-Founder, Pres, CEO & Director -
Sven Guenther,
Executive Vice President - Research and Development -
R. LaDuane Clifton,
Chief Financial Officer, Treasurer, Secretary -
Dr. Travis C. Mickle,
Co-Founder, Chairman, Pres & CEO -
Dr. Sven Guenther,
Exec. VP of R&D -
R. LaDuane Clifton CPA,
CFO, Sec. & Treasurer -
Richard W. Pascoe,
Exec. Chairman -
Jason Rando,
IR Contact Officer -
David Tierney,
Independent Director -
Joseph Saluri,
Independent Director -
Matthew Plooster,
Independent Director -
Richard Pascoe,
Lead Independent Director -
Timothy Sangiovanni,
Vice President, Corporate Controller -
Timothy J. Sangiovanni CPA,
VP & Corp. Controller -
Dr. Andrew Barrett,
VP of Scientific Affairs -
Christal M. M. Mickle,
Co-Founder and VP of Operations & Product Devel. -
Tracy M Woody,
Chief Commercial Officer -
Danny L Thompson,
Director -
Gordon K Johnson,
Chief Business Officer -
Daniel L Cohen,
EVP, Govt. & Public Relations -
Christal M M Mickle,
Chief Product Dev. Officer -
Joshua Schafer,
CCO & EVP, Bus. Development -
Samuel J Braun,
10% owner -
Tamara A Favorito,
Director